Dr. Maria Badikyan, our research fellow, is leading a study on Philadelphia negative myeloproliferative neoplasms (MPNs), a group of disorders of the myeloid stem cells that include primary myelofibrosis, polycythaemia vera, and essential thrombocythaemia. A significant number of individuals with MPNs have the JAK2(V617F) mutation. With the mentorship of Dr. Astghik Voskanyan, Dr. Badikyan is investigating the correlation between JAK2 (V617F) allele burden and various factors such as MPN type, clinical symptoms, and laboratory test results at the time of presentation among patients with Ph-negative MPN.
Approximately 200 patients diagnosed with myeloproliferative disorders in accordance with the World Health Organization's diagnostic criteria will be enrolled in this study. Blood samples of patients will be analyzed for JAK2 (V617F) allele burden at several time points throughout the study using a quantitative real-time polymerase chain reaction (PCR) assay.
Moreover, this study aims to investigate whether the reduction of JAK2 p.V617F allele burden during cytoreductive therapy is correlated with improved disease outcomes, and whether the persisting or increasing level of mutant allele burden is predictive of disease progression and/or transformation to acute leukemia or evolution to myelofibrosis. This will be possible through the long-term follow-up of participants.
The study's findings will advance our understanding of the role of JAK2V617F allele burden in Ph-negative MPN and may have important implications for the treatment and management of these patients.
About IMMONC
Immune Oncology Research Institute (IMMONC) is dedicated to advancing research aimed at preventing, treating, and ultimately curing cancer while making these innovations accessible to those who need them. If you're interested in joining our team, please feel free to contact us at [email protected] or at +374-41 310-048.